Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1140582

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to issue guidance to health professionals on the Serious Shortage Protocol.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279389
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:34:54 answering member 4455 label Biography information for Seema Kennedy previous answer version 131086 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140584

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Government has provide information to patients on changes to the provision of medicines as a result of the serious shortage protocol; and if he will make a statement.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279390
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279391 question first answered 26/07/2019 11:36:12 answering member 4455 label Biography information for Seema Kennedy previous answer version 131087 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140585

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions the Government has had with (a) patient groups and (b) professional bodies on the development of the serious shortage protocol.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279391
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279390 question first answered 26/07/2019 11:36:13 answering member 4455 label Biography information for Seema Kennedy previous answer version 131085 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140586

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Migraines: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to ensure the adequacy of provision of treatment for people with migraines.
	tabling member constituency	Ealing, Southall
	tabling member printed	Mr Virendra Sharma
	uin	279402
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The majority of patients with migraine can be managed through routine access to primary and secondary care. Migraine management is identified within the core competencies for the care for people with neurological conditions in the Royal College of General Practitioners’ (RCGP) GP curriculum. Migraines are also identified as an key area of clinical knowledge in the RCGP Applied Knowledge Test (AKT) content guide. The AKT is a summative assessment of the knowledge base that underpins general practice in the United Kingdom within the context of the National Health Service and is a key part of GPs’ qualifying exams. <br></p><p>The National Institute for Health and Care Excellence (NICE) guideline, ‘Headaches: Diagnosis and management of headaches in young people and adults’, published in 2012 and updated in 2015, sets out evidence based best practice for healthcare professionals in the care, treatment and support of people who suffer from migraines.</p><p> </p><p>The usual treatment approaches to migraine are designed to either stop or prevent attacks. Treatments for acute migraine attacks include medications such as analgesics, triptans and anti-emetics (as recommended in NICE's guideline on headaches in over 12s).</p><p>Treatments to stop or reduce the frequency of migraine attacks include medications such as beta blockers, tricyclic antidepressants and antiepileptics.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:39:12 answering member 4455 label Biography information for Seema Kennedy previous answer version 131084 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1604 label Biography information for Mr Virendra Sharma

1140602

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 July 2019 to Question 273399 on HIV Infection: Salford, if he will take steps to ensure that gay and bisexual men in Salford have access to PrEP.
	tabling member constituency	Salford and Eccles
	tabling member printed	Rebecca Long Bailey
	uin	279454
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The pre-exposure prophylaxis (PrEP) Impact Trial is managed by the Trial Sponsor. Recruitment to places in the Trial is managed locally by participating clinics. Following funding from NHS England to pay for extra PrEP drug and research costs and the my Rt. hon Friend the Secretary of State for Health and Social Care’s announcement on 30 January that the number of places on the PrEP Impact Trial would be doubled to 26,000, expansion of the Trial is now underway across the country. Participation in the Trial is on a voluntary basis and it is for research clinics and local authorities to decide whether they wish to take part and the number of allocated places they can accept.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 12:17:05 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4396 label Biography information for Rebecca Long Bailey

1140170

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases and Strokes: Females
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will respond to the recommendations in the report entitled Call for Action: Inquiry into heart attack and stroke, published by the all-party Parliamentary group on women’s health in July 2019; and if he will make a statement.
	tabling member constituency	Dewsbury
	tabling member printed	Paula Sherriff
	uin	279083
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>NHS England has acknowledged the recently published report and will be considering the content.</p><p>Improving the prevention and treatment of heart attacks and stroke are key aims in the NHS Long Term Plan, with an important milestone being for the National Health Service to help prevent up to 150,000 heart attacks, strokes and dementia cases over the next 10 years. The NHS Long Term Plan highlights that outcomes from heart attack and stroke can be improved, and that there should be a focus on inequalities.</p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 23/07/2019 16:54:04 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4426 label Biography information for Paula Sherriff

1140171

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases and Strokes: Females
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve (a) outcomes, (b) early identification and (c) treatment of heart attack and stroke for women.
	tabling member constituency	Dewsbury
	tabling member printed	Paula Sherriff
	uin	279084
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Improving the prevention and treatment of heart attacks and stroke are key aims in the NHS Long Term Plan, with an important milestone being for the National Health Service to help prevent up to 150,000 heart attacks, strokes and dementia cases over the next 10 years. The NHS Long Term Plan highlights that outcomes from heart attack and stroke can be improved, and that there should be a focus on inequalities.</p><p>In addition, addressing variations in outcomes from cardiovascular disease (CVD), such as heart attacks and stroke, is one of Public Health England’s (PHE) top priorities, and in February 2019, PHE announced new 10-year CVD ambitions for England, which are intended to complement the NHS Long Term Plan and are the first ever national ambitions to improve the detection and treatment of the major causes of CVD.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 23/07/2019 16:48:22 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4426 label Biography information for Paula Sherriff

1140190

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Compensation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much was spent by the NHS on settling compensation claims in the last 12 months.
	tabling member constituency	Hendon
	tabling member printed	Dr Matthew Offord
	uin	278968
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>NHS Resolution operates both clinical and non-clinical schemes for dealing with claims made against NHS organisations and independent sector providers of National Health Service care in England. Its latest Annual Report, published on 11 July 2019, shows the payments (damages, claimant and defence costs) relating to claims for the financial year 2018-19 was £2,422 million.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 12:02:34 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4006 label Biography information for Dr Matthew Offord

1140209

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions there have been between Vertex Pharmaceuticals and NHS England with on cystic fibrosis medicines.
	tabling member constituency	Bristol East
	tabling member printed	Kerry McCarthy
	uin	278928
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278929 question first answered 23/07/2019 16:49:59 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1491 label Biography information for Kerry McCarthy

1140210

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will set a deadline for NHS England and Vertex Pharmaceuticals to come to an agreement to enable access to cystic fibrosis medicines produced by that company.
	tabling member constituency	Bristol East
	tabling member printed	Kerry McCarthy
	uin	278929
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278928 question first answered 23/07/2019 16:49:59 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1491 label Biography information for Kerry McCarthy